NCT04572516View on ClinicalTrials.gov

Botulium Toxin Type A In Non Infectious Chronic Rhinosinusitis

PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 1, 2020

Primary Completion Date

June 15, 2021

Study Completion Date

July 15, 2021

Conditions
Chronic Rhinosinusitis (Diagnosis)
Interventions
DRUG

BTX A Topical

In group A (topical group) ,topical application in the form of merocel soaked with 20 units of BTX\_A (2ml) will be placed at each side of the nasal cavity for 30 minutes.

DRUG

BTX A Injection

In group B (injected group), 20 units of BTX\_A(2ml) will be injected submucosally in each inferior turbinate using insulin syringe needle after local anesthesia using 10% xylocaine spray .

Trial Locations (1)

13512

Benha University Hospital, Faculty of Medicine, Banhā

All Listed Sponsors
lead

Benha University

OTHER

NCT04572516 - Botulium Toxin Type A In Non Infectious Chronic Rhinosinusitis | Biotech Hunter | Biotech Hunter